1-20 of 30
canagliflozin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink
Journal: Diabetes Care
Diabetes Care 2022;45(11):2644–2652
https://doi.org/10.2337/dc22-0866
Published: 22 September 2022
View article titled, Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
Open the PDF for Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS in another window
Journal Articles

Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)

Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, Vasilis Tsimihodimos, Fisseha Tesfaye, Wayne Shaw, Norman Rosenthal, Gemma A. Figtree, Bruce Neal, Kenneth W. Mahaffey, Vlado Perkovic, Michael K. Hansen
Journal: Diabetes Care
Diabetes Care 2022;45(8):1893–1899
https://doi.org/10.2337/dc21-2398
Published: 26 July 2022
View article titled, Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Open the PDF for Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS) in another window
Journal Articles

Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes

Evangelos K. Oikonomou, Marc A. Suchard, Darren K. McGuire, Rohan Khera
Journal: Diabetes Care
Diabetes Care 2022;45(4):965–974
https://doi.org/10.2337/dc21-1765
Published: 04 February 2022
View article titled, Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes
Open the PDF for Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes in another window
Journal Articles

Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

James L. Januzzi, Jr., Javed Butler, Naveed Sattar, Jialin Xu, Wayne Shaw, Norman Rosenthal, Michael Pfeifer, Kenneth W. Mahaffey, Bruce Neal, Michael K. Hansen
Journal: Diabetes Care
Diabetes Care 2021;44(1):210–216
https://doi.org/10.2337/dc20-1889
Published: 06 November 2020
View article titled, Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study
Open the PDF for Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study in another window
Journal Articles

In This Issue of Diabetes Care

Journal: Diabetes Care
Diabetes Care 2020;43(6):1167–1168
https://doi.org/10.2337/dc20-ti06
Published: 12 May 2020
View article titled, In This Issue of <em>Diabetes Care</em>
Open the PDF for In This Issue of <em>Diabetes Care</em> in another window
Journal Articles

Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors

Hui Shao, Lizheng Shi, Vivian A. Fonseca
Journal: Diabetes Care
Diabetes Care 2020;43(7):1530–1536
https://doi.org/10.2337/dc20-0227
Published: 28 April 2020
View article titled, Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Open the PDF for Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors in another window
Journal Articles

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes

Ali Muhammed Ali, Robert Martinez, Hussein Al-Jobori, John Adams, Curtis Triplitt, Ralph DeFronzo, Eugenio Cersosimo, Muhammad Abdul-Ghani
Journal: Diabetes Care
Diabetes Care 2020;43(6):1234–1241
https://doi.org/10.2337/dc18-2460
Published: 27 March 2020
View article titled, Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 Diabetes
Open the PDF for Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018

Chintan V. Dave, Sebastian Schneeweiss, Deborah J. Wexler, Gregory Brill, Elisabetta Patorno
Journal: Diabetes Care
Diabetes Care 2020;43(4):921–924
https://doi.org/10.2337/dc19-1943
Published: 10 February 2020
View article titled, Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018
Open the PDF for Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013–2018 in another window
Includes: Supplementary data
Journal Articles

Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes

Devin Abrahami, Antonios Douros, Hui Yin, Oriana H.Y. Yu, Laurent Azoulay
Journal: Diabetes Care
Diabetes Care 2019;42(9):e150–e152
https://doi.org/10.2337/dc19-0849
Published: 11 July 2019
View article titled, Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
Open the PDF for Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes in another window
Journal Articles

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?

Matthew C. Riddle, William T. Cefalu
Journal: Diabetes Care
Diabetes Care 2018;41(12):2444–2447
https://doi.org/10.2337/dci18-0041
Published: 12 November 2018
View article titled, SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Open the PDF for SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True? in another window
Journal Articles

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter, Itamar Raz, Julio Rosenstock, Matthew C. Riddle
Journal: Diabetes Care
Diabetes Care 2018;41(1):14–31
https://doi.org/10.2337/dci17-0057
Published: 11 December 2017
View article titled, Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum
Open the PDF for Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum in another window
Includes: Supplementary data
Journal Articles

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis

Girish N. Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E. Grams, Steven G. Coca
Journal: Diabetes Care
Diabetes Care 2017;40(11):1479–1485
https://doi.org/10.2337/dc17-1011
Published: 21 August 2017
View article titled, Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Open the PDF for Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis in another window
Includes: Supplementary data
Journal Articles

Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series

Harindra Rajasekeran, S. Joseph Kim, Carl J. Cardella, Jeffrey Schiff, Mark Cattral, David Z.I. Cherney, Sunita K.S. Singh
Journal: Diabetes Care
Diabetes Care 2017;40(7):e75–e76
https://doi.org/10.2337/dc17-0237
Published: 17 April 2017
View article titled, Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series
Open the PDF for Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series in another window
Journal Articles

Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

Priscilla Hollander, Harold E. Bays, Julio Rosenstock, Mary Ellen Frustaci, Albert Fung, Frank Vercruysse, Ngozi Erondu
Journal: Diabetes Care
Diabetes Care 2017;40(5):632–639
https://doi.org/10.2337/dc16-2427
Published: 13 March 2017
View article titled, Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial
Open the PDF for Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes

Helena W. Rodbard, Anne L. Peters, April Slee, Anjun Cao, Shana B. Traina, Maria Alba
Journal: Diabetes Care
Diabetes Care 2017;40(2):171–180
https://doi.org/10.2337/dc16-1353
Published: 29 November 2016
View article titled, The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
Open the PDF for The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes

Anne L. Peters, Robert R. Henry, Payal Thakkar, Cindy Tong, Maria Alba
Journal: Diabetes Care
Diabetes Care 2016;39(4):532–538
https://doi.org/10.2337/dc15-1995
Published: 15 March 2016
View article titled, Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes
Open the PDF for Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes

Julio Rosenstock, Leonard Chuck, Manuel González-Ortiz, Kate Merton, Jagriti Craig, George Capuano, Rong Qiu
Journal: Diabetes Care
Diabetes Care 2016;39(3):353–362
https://doi.org/10.2337/dc15-1736
Published: 19 January 2016
View article titled, Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes
Open the PDF for Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686

Ketan Dhatariya
Journal: Diabetes Care
Diabetes Care 2016;39(1):e18
https://doi.org/10.2337/dc15-1956
Published: 14 December 2015
View article titled, Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686
Open the PDF for Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686 in another window
Journal Articles

Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686

Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2016;39(1):e19
https://doi.org/10.2337/dci15-0026
Published: 14 December 2015
View article titled, Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686
Open the PDF for Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680–1686 in another window
Journal Articles

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R. Henry
Journal: Diabetes Care
Diabetes Care 2015;38(12):2344–2353
https://doi.org/10.2337/dc15-0642
Published: 19 November 2015
View article titled, Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: <subtitle>From Bench to Bedside</subtitle>
Open the PDF for Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: <subtitle>From Bench to Bedside</subtitle> in another window
Includes: Supplementary data